Attached files
| file | filename |
|---|---|
| 8-K - 8-K - AtriCure, Inc. | atrc-20200728x8k.htm |
|
Exhibit 99.1 |
July 28, 2020
AtriCure Reports Second Quarter 2020 Financial Results
|
· |
Worldwide revenue of $40.8 million – a decrease of 30.7% year over year |
|
· |
U.S. revenue of $33.7 million – a decrease of 28.6% year over year |
|
· |
International revenue of $7.1 million – a decrease of 39.0% year over year |
MASON, Ohio, July 28, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results.
“Amidst tremendous uncertainty in this challenging environment, our team at AtriCure has shown both resiliency and leadership without missing a beat. We are continuing to support our clinician partners in creative and evolving ways while maintaining our patient-first culture,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We are pleased by our second quarter results, which as expected, experienced a trough in April, then a rapid return in May, followed by steady volumes through June. In addition, we achieved significant milestones on our strategic initiatives with the release of the CONVERGE clinical trial data in May as well as further progress on aMAZE, continued success with Cryo Nerve Block, and ongoing training and education programs.”
Mr. Carrel continued, “While we are encouraged by the improvement in our business throughout the second quarter, we have begun to experience more regional variability and procedure slowdowns in July in response to the recent resurgence of COVID-19 cases and related restrictions. Despite the continued uncertainty, as we look forward, we are extremely confident about our future. We were able to strengthen our balance sheet this quarter, allowing us to continue to invest in our people as well as our pillars to ensure that AtriCure is well positioned for durable growth over the next several years with a robust pipeline of clinical and product innovation.”
Second Quarter 2020 Financial Results
Revenue for the second quarter of 2020 was $40.8 million, a decrease of $18.1 million or 30.7% (a decrease of 30.6% on a constant currency basis), compared to second quarter 2019 revenue. U.S. revenue decreased 28.6% to $33.7 million, and international revenue decreased 39.0% to $7.1 million, (a decrease of 38.5% on a constant currency basis), compared to second quarter 2019 revenue.
Gross profit for the second quarter of 2020 was $27.7 million compared to $43.9 million for the second quarter of 2019. Gross margin for the second quarter of 2020 decreased to 67.7% compared to 74.5% in the second quarter of 2019.
Loss from operations for the second quarter of 2020 was $7.3 million, compared to $3.8 million for the second quarter of 2019. Net loss per share was $0.20 for the second quarter of 2020 compared to $0.11 for the second quarter of 2019.
Adjusted EBITDA was a loss of $6.1 million for the second quarter of 2020 compared to positive $1.4 million for the second quarter of 2019. Adjusted loss per share for the second quarter of 2020 was $0.38 compared to an adjusted loss per share of $0.17 for the second quarter of 2019. Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP measures. We discuss these non-GAAP measures and provide reconciliations to GAAP measures later in this release.
2020 Financial Guidance
As previously reported, AtriCure is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.
Conference Call
AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2020 to discuss its second quarter 2020 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 6338708. A live audio webcast of the presentation
may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
Forward-Looking Statements
This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/fls as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We do not undertake to update our forward-looking statements. Actual results could differ materially.
Use of Non-GAAP Financial Measures
To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure uses certain non-GAAP financial measures in this release as supplemental financial metrics.
Revenue reported on a constant currency basis is a non-GAAP measure and is calculated by applying previous period foreign currency exchange rates, which are determined by the average daily Euro to Dollar exchange rate, to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and the Company’s investors.
Adjusted EBITDA is calculated as Net loss before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, and change in fair value of contingent consideration liabilities. Management believes in order to properly understand the short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning, and previously used adjusted EBITDA as a performance metric in the annual incentive plan. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods can be found in the table captioned “Reconciliation of Non-GAAP Adjusted (Loss) Income (Adjusted EBITDA)” later in this release.
Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments to expenses related to the adjustment in value of contingent consideration liabilities. Management believes this metric provides a better measure of comparability of results between periods, as such adjustments can be significant and vary in value and are not reflective of our core business. A reconciliation of adjusted loss per share reported in this release to the most comparable GAAP measure for the respective periods can be found in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release.
The non-GAAP financial measures used by AtriCure may not be the same or calculated the same as those used by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP.
CONTACTS:
Andy Wade
AtriCure, Inc.
Chief Financial Officer
(513) 755-4564
awade@atricure.com
Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
lynn@gilmartinir.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ATRICURE, INC. AND SUBSIDIARIES |
|||||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||
|
(In Thousands, Except Per Share Amounts) |
|||||||||||
|
(Unaudited) |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||
|
United States Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Open ablation |
$ |
15,550 |
|
$ |
20,561 |
|
$ |
34,768 |
|
$ |
39,557 |
|
Minimally invasive ablation |
|
4,755 |
|
|
9,092 |
|
|
11,316 |
|
|
16,854 |
|
Appendage management |
|
13,021 |
|
|
16,498 |
|
|
30,440 |
|
|
32,168 |
|
Total ablation and appendage management |
|
33,326 |
|
|
46,151 |
|
|
76,524 |
|
|
88,579 |
|
Valve tools |
|
338 |
|
|
1,014 |
|
|
613 |
|
|
1,590 |
|
Total United States |
|
33,664 |
|
|
47,165 |
|
|
77,137 |
|
|
90,169 |
|
International Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Open ablation |
|
3,744 |
|
|
6,792 |
|
|
8,859 |
|
|
13,092 |
|
Minimally invasive ablation |
|
1,109 |
|
|
1,935 |
|
|
2,654 |
|
|
4,064 |
|
Appendage management |
|
2,271 |
|
|
2,977 |
|
|
5,333 |
|
|
5,431 |
|
Total ablation and appendage management |
|
7,124 |
|
|
11,704 |
|
|
16,846 |
|
|
22,587 |
|
Valve tools |
|
36 |
|
|
37 |
|
|
66 |
|
|
116 |
|
Total international |
|
7,160 |
|
|
11,741 |
|
|
16,912 |
|
|
22,703 |
|
Total revenue |
|
40,824 |
|
|
58,906 |
|
|
94,049 |
|
|
112,872 |
|
Cost of revenue |
|
13,170 |
|
|
15,013 |
|
|
27,511 |
|
|
29,108 |
|
Gross profit |
|
27,654 |
|
|
43,893 |
|
|
66,538 |
|
|
83,764 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
10,036 |
|
|
9,804 |
|
|
21,623 |
|
|
17,980 |
|
Selling, general and administrative expenses |
|
24,903 |
|
|
37,928 |
|
|
67,654 |
|
|
74,943 |
|
Total operating expenses |
|
34,939 |
|
|
47,732 |
|
|
89,277 |
|
|
92,923 |
|
Loss from operations |
|
(7,285) |
|
|
(3,839) |
|
|
(22,739) |
|
|
(9,159) |
|
Other expense, net |
|
(939) |
|
|
(252) |
|
|
(1,885) |
|
|
(501) |
|
Loss before income tax expense |
|
(8,224) |
|
|
(4,091) |
|
|
(24,624) |
|
|
(9,660) |
|
Income tax expense |
|
12 |
|
|
10 |
|
|
20 |
|
|
76 |
|
Net loss |
$ |
(8,236) |
|
$ |
(4,101) |
|
$ |
(24,644) |
|
$ |
(9,736) |
|
Basic and diluted net loss per share |
$ |
(0.20) |
|
$ |
(0.11) |
|
$ |
(0.61) |
|
$ |
(0.26) |
|
Weighted average shares used in computing net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
41,649 |
|
|
37,334 |
|
|
40,160 |
|
|
37,156 |
|
|
|
|
|
|
|
|
ATRICURE, INC. AND SUBSIDIARIES |
|||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||
|
(In Thousands) |
|||||
|
(Unaudited) |
|||||
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
||
|
|
2020 |
|
2019 |
||
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash, cash equivalents, and short-term investments |
$ |
232,498 |
|
$ |
81,801 |
|
Accounts receivable, net |
|
22,892 |
|
|
28,046 |
|
Inventories |
|
32,809 |
|
|
29,414 |
|
Prepaid and other current assets |
|
3,835 |
|
|
3,899 |
|
Total current assets |
|
292,034 |
|
|
143,160 |
|
Property and equipment, net |
|
30,236 |
|
|
32,646 |
|
Operating lease right-of-use assets |
|
2,573 |
|
|
4,032 |
|
Long-term investments |
|
15,339 |
|
|
12,675 |
|
Goodwill and intangible assets, net |
|
363,685 |
|
|
364,662 |
|
Other noncurrent assets |
|
366 |
|
|
705 |
|
Total assets |
$ |
704,233 |
|
$ |
557,880 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable and accrued liabilities |
$ |
30,351 |
|
$ |
47,698 |
|
Other current liabilities and current maturities of debt and leases |
|
7,701 |
|
|
2,218 |
|
Total current liabilities |
|
38,052 |
|
|
49,916 |
|
Long-term debt |
|
54,154 |
|
|
59,634 |
|
Finance lease liabilities |
|
11,377 |
|
|
11,774 |
|
Operating lease liabilities |
|
1,581 |
|
|
2,796 |
|
Contingent consideration and other noncurrent liabilities |
|
182,207 |
|
|
186,417 |
|
Total liabilities |
|
287,371 |
|
|
310,537 |
|
Stockholders' equity: |
|
|
|
|
|
|
Common stock |
|
45 |
|
|
40 |
|
Additional paid-in capital |
|
723,754 |
|
|
529,658 |
|
Accumulated other comprehensive loss |
|
(96) |
|
|
(158) |
|
Accumulated deficit |
|
(306,841) |
|
|
(282,197) |
|
Total stockholders' equity |
|
416,862 |
|
|
247,343 |
|
Total liabilities and stockholders' equity |
$ |
704,233 |
|
$ |
557,880 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ATRICURE, INC. AND SUBSIDIARIES |
|||||||||||
|
RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS |
|||||||||||
|
(In Thousands) |
|||||||||||
|
(Unaudited) |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Non-GAAP Adjusted (Loss) Income (Adjusted EBITDA) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||
|
Net loss, as reported |
$ |
(8,236) |
|
$ |
(4,101) |
|
$ |
(24,644) |
|
$ |
(9,736) |
|
Income tax expense |
|
12 |
|
|
10 |
|
|
20 |
|
|
76 |
|
Other expense, net |
|
939 |
|
|
252 |
|
|
1,885 |
|
|
501 |
|
Depreciation and amortization expense |
|
2,458 |
|
|
2,362 |
|
|
4,902 |
|
|
4,590 |
|
Share-based compensation expense |
|
6,193 |
|
|
4,375 |
|
|
10,577 |
|
|
8,529 |
|
Contingent consideration adjustment |
|
(7,504) |
|
|
(2,205) |
|
|
(5,046) |
|
|
(3,872) |
|
Acquisition costs |
|
39 |
|
|
713 |
|
|
138 |
|
|
827 |
|
Non-GAAP adjusted (loss) income (adjusted EBITDA) |
$ |
(6,099) |
|
$ |
1,406 |
|
$ |
(12,168) |
|
$ |
915 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Non-GAAP Adjusted Loss Per Share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||
|
Net loss, as reported |
$ |
(8,236) |
|
$ |
(4,101) |
|
$ |
(24,644) |
|
$ |
(9,736) |
|
Contingent consideration adjustment |
|
(7,504) |
|
|
(2,205) |
|
|
(5,046) |
|
|
(3,872) |
|
Net loss excluding contingent consideration adjustment |
$ |
(15,740) |
|
$ |
(6,306) |
|
$ |
(29,690) |
|
$ |
(13,608) |
|
Basic and diluted adjusted net loss per share |
$ |
(0.38) |
|
$ |
(0.17) |
|
$ |
(0.74) |
|
$ |
(0.37) |
|
Weighted average shares used in computing adjusted net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
41,649 |
|
|
37,334 |
|
|
40,160 |
|
|
37,156 |